FCX vs PPCB · P/E 38, rev $25.45B vs P/E 0.0, $3.9M cap
Freeport-McMoran Copper & Gold Inc (FCX) versus Propanc Biopharma, Inc. Common Stock (PPCB) — a side-by-side from cached financials, not a winner call.
Freeport-McMoran Copper & Gold Inc (FCX) is a copper company listed on US.
Propanc Biopharma, Inc. Common Stock (PPCB) is a biotechnology company listed on NASDAQ.
Latest reported FCX revenue for 2024-12-31 was $25.45B. Net income was $4.40B. Revenue was up 11.4% from 2023-12-31 to 2024-12-31. FCX currently screens at market cap $67.80B and trailing P/E 38.0.
PPCB does not have a complete income-statement cache yet.
FCX currently screens at market cap $67.80B and trailing P/E 38.0. PPCB currently screens at market cap $3.9M and trailing P/E 0.0.
Not investment advice. Open the FCX and PPCB stock pages for the full models.
Not investment advice.